

DAFTAR PUSTAKA

- Abdel-Misih, S.R., & Bloomston, M., 2010. Liver Anatomy. *Surg Clin North Am* 90: 643–653. doi:10.1016/j.suc.2010.04.017.Liver
- Adigun, O.O., Yarappu, S.N.Y., Zubair, M., & Khetarpal, S., 2024. Alpha-Fetoprotein Analysis [WWW Document]. *StatPearls Publ.* URL https://www.ncbi.nlm.nih.gov/books/NBK430750/?utm_source=chatgpt.com (accessed 8.21.25).
- Akkiz, H., Carr, B.I., Kuran, S., Karaoğullarından, Ü., Üsküdar, O., Tokmak, S., et al., 2018. Macroscopic Portal Vein Thrombosis in HCC Patients. *Can. J. Gastroenterol. Hepatol.* 2018. doi:10.1155/2018/3120185
- Altman, D.G., 1990. Practical Statistics for Medical Research, Practical Statistics for Medical Research. doi:10.1201/9780429258589
- American College of Radiology, 2018. Liver Imaging Reporting and Data System (LI-RADS) v2018 [WWW Document]. *ACR.org.* URL <https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/RADS/LI-RADS/LI-RADS-CT-MRI-2018-Core.pdf> (accessed 8.27.25).
- Arrieta, O., Cacho, B., Morales-Espinosa, D., Ruelas-Villavicencio, A., Flores-Estrada, D., & Hernández-Pedro, N., 2007. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. *BMC Cancer* 7: 1–9. doi:10.1186/1471-2407-7-28
- Broadhurst, P., Toyoda, H., Kumada, T., Schweitzer, N., Vogel, A., Benckert, J., et al., 2017. Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study. *J. Hepatol.* 66. doi:10.1016/s0168-8278(17)31684-7
- Bruix, J., & Sherman, M., 2011. AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma : An Update. *Hepatology* 53: 1020–1022. doi:10.1002/hep.24199
- Brunicaardi, F.C., Andersen, D.K., Biliar, T.R., Dunn, D.L., Hunter, J.G., Matthews, J.B., et al., 2015. Schwartz’s Principles of Surgery, Tenth Edit. ed, McGraw-Hill Education. New York. doi:10.1097/00007611-190902030-00015
- Cerrito, L., Annicchiarico, B.E., Iezzi, R., Gasbarrini, A., Pompili, M., & Ponziani, F.R., 2019. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. *World J. Gastroenterol.* 25: 4360–4382. doi:10.3748/wjg.v25.i31.4360
- Chan, S.L., Mo, F., Johnson, P.J., Siu, D.Y.W., Chan, M.H.M., Lau, W.Y., et al., 2014. Performance of serum α -fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. *Hpb* 16: 366–372. doi:10.1111/hpb.12146

- Chen, H.Y., Tsai, H.I., Yu, M.C., Lee, W.C., Wang, C.C., Hsieh, J.C.H., et al., 2025. Tumor size larger than 6.5 cm and microvascular invasion are comparable prognosticators for hepatocellular carcinoma: a multi-institutional observational study. *Clin. Transl. Oncol.* doi:10.1007/s12094-025-03981-3
- Chen, W., Peng, J., Ye, J., Dai, W., Li, G., & He, Y., 2020. Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis. *J. Cancer* 11: 403–413. doi:10.7150/jca.31435
- Chen, Y.W., Pan, H. Ben, Tseng, H.H., Hung, Y.T., Huang, J.S., & Chou, C.P., 2013. Assessment of blood flow in hepatocellular carcinoma: Correlations of computed tomography perfusion imaging and circulating angiogenic factors. *Int. J. Mol. Sci.* 14: 17536–17552. doi:10.3390/ijms140917536
- Cheng, A.L., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T.Y., et al., 2022. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J. Hepatol.* 76: 862–873. doi:10.1016/j.jhep.2021.11.030
- Cheng, J., Wang, W., Zhang, Y., Liu, X., Li, M., Wu, Z., et al., 2014. Prognostic Role of Pre-Treatment Serum AFP-L3 % in Hepatocellular Carcinoma: Systematic Review and Meta- Analysis 9. doi:10.1371/journal.pone.0087011
- Chernyak, V., Fowler, K.J., Kamaya, A., Kielar, A.Z., Elsayes, K.M., Bashir, M.R., et al., 2018. Liver Imaging Reporting and Data System (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. *Radiology* 289: 816–830. doi:10.1148/radiol.2018181494
- Choi, J.H., & Thung, S.N., 2023. Advances in Histological and Molecular Classification of Hepatocellular Carcinoma. *Biomedicines* 11. doi:10.3390/biomedicines11092582
- Choi, T.W., Joo, I., & Kim, H.C., 2022. Association of dysmorphic intratumoral vessel with high lung shunt fraction in patients with hepatocellular carcinoma. *Sci. Rep.* 12: 1–7. doi:10.1038/s41598-022-18697-5
- Cruz, C.R., Rita, A., Ribeiro, M., César, A., Maranhão, N., Aroucha, D.B., et al., 2021. Clinical and laboratory parameters associated with li-rads as diagnostic of liver nodule in patients with cirrhosis 1–11. doi:10.21037/tgh.2020.01.05
- Dahlan, M., 2016. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan, Sagung Seto.
- De Muzio, F., Grassi, F., Dell’aversana, F., Fusco, R., Danti, G., Flammia, F., et al., 2022. A Narrative Review on LI- RADS Algorithm in Liver Tumors: Prospects and Pitfalls. *Diagnostics* 12. doi:10.3390/diagnostics12071655
- Demirjian, A., Peng, P., Geschwind, J.F.H., Cosgrove, D., Schutz, J., Kamel, I.R., et al., 2011. Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest. *J. Gastrointest. Surg.* 15: 2089–2097. doi:10.1007/s11605-011-1614-7

- Dhamija, M., Vidyarthi, G., Boyd, W., & Amodeo, D., 2011. Objective Response of AFP with Chemoembolization. *Am. J. Gastroenterol.* 106. doi:10.14309/00000434-201110002-00299
- Di Bisceglie, A.M., & Hoofnagle, J.H., 1989. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. *Cancer* 64. doi:10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7
- Di Bisceglie, A.M., Sterling, R.K., Chung, R.T., Everhart, J.E., Dienstag, J.L., Bonkovsky, H.L., et al., 2005. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. *J. Hepatol.* 43. doi:10.1016/j.jhep.2005.03.019
- Ehman, E.C., Behr, S.C., Umetsu, S.E., Fidelman, N., Yeh, B.M., Ferrell, L.D., et al., 2016. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. *Abdom. Radiol.* 41: 963–969. doi:10.1007/s00261-015-0623-5
- El-Serag, H.B., 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* 142: 1264-1273.e1. doi:10.1053/j.gastro.2011.12.061
- Elsayes, K.M., Kielar, A.Z., Chernyak, V., Morshid, A., Furlan, A., Masch, W.R., et al., 2019. <p>LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance</p>. *J. Hepatocell. Carcinoma* Volume 6: 49–69. doi:10.2147/jhc.s186239
- Farazi, P.A., & DePinho, R.A., 2006. Hepatocellular carcinoma pathogenesis: From genes to environment. *Nat. Rev. Cancer* 6: 674–687. doi:10.1038/nrc1934
- Finn, R.S., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T.-Y., et al., 2020. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N. Engl. J. Med.* 382: 1894–1905. doi:10.1056/nejmoa1915745
- Fornier, A., Reig, M., & Bruix, J., 2018. Hepatocellular carcinoma. *Lancet* 391: 1301–1314. doi:10.1016/S0140-6736(18)30010-2
- Francis, I.R., Cohan, R.H., McNulty, N.J., Platt, J.F., Korobkin, M., Gebremariam, A., et al., 2003. Multidetector CT of the Liver and Hepatic Neoplasms : Effect of Conspicuity and Vascular Enhancement 1217–1224.
- Galle, P.R., Fornier, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J.L., et al., 2018. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol.* 69: 182–236. doi:10.1016/j.jhep.2018.03.019
- Głowska-ciemny, J., Szmyt, K., Kuszerska, A., Rzepka, R., Kaisenberg, C. Von, & Kocyłowski, R., 2024. Fetal and Placental Causes of Elevated Serum Alpha-Fetoprotein Levels in Pregnant Women.
- Goldstein, N.S., Blue, D.E., Hankin, R., Hunter, S., Bayati, N., Silverman, A.L., et al., 1999. Serum α -fetoprotein levels in patients with chronic hepatitis C: Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. *Am. J. Clin. Pathol.* 111.

doi:10.1093/ajcp/111.6.811

- Gopal, P., Yopp, A.C., Waljee, A.K., Chiang, J., Nehra, M., Kandunoori, P., et al., 2014. Factors that affect accuracy of α -fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. *Clin. Gastroenterol. Hepatol.* 12. doi:10.1016/j.cgh.2013.09.053
- Guo, J., Seo, Y., Ren, S., Hong, S., Lee, D., Kim, S., et al., 2016. Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoteric acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. *Abdom. Radiol.* 41: 1960–1972. doi:10.1007/s00261-016-0807-7
- Hallgren, K.A., 2012. Computing Inter-Rater Reliability for Observational Data: An Overview and Tutorial. *Tutor. Quant. Methods Psychol.* 8. doi:10.20982/tqmp.08.1.p023
- Hanif, H., Ali, M.J., Khan, I.W., Luna-Cuadros, M.A., Khan, M.M., Tan-Yeung Lau, D., et al., 2022. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. *World J. Gastroenterol.* doi:10.3748/wjg.v28.i2.216
- Hayashi, K., Kumada, T., Nakano, S., Takeda, I., Sugiyama, K., Kiriya, S., et al., 1999. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of α -fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. *Am. J. Gastroenterol.* 94. doi:10.1016/S0002-9270(99)00434-7
- Hennedige, T., & Venkatesh, S.K., 2016. 2016 Hepatocellular Carcinoma : Global view Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma 22: 205–220. doi:10.3748/wjg.v22.i1.205
- Hennedige, T., & Venkatesh, S.K., 2012. Imaging of hepatocellular carcinoma: Diagnosis, staging and treatment monitoring. *Cancer Imaging* 12: 530–547. doi:10.1102/1470-7330.2012.0044
- Ho, J.K.H., Thuraiajah, P.H., Leo, J., Huang, D.Q.Y., & Fan, K.H., 2024. Sex differences in hepatocellular carcinoma. *Hepatoma Res.* 10: 1–11. doi:10.20517/2394-5079.2024.119
- Hu, X., Chen, R., Wei, Q., & Xu, X., 2022. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? *Int. J. Biol. Sci.* 18: 536–551. doi:10.7150/ijbs.64537
- Huang, L., Wang, Z., & Lu, J., 2024. Diagnosis and treatment of hepatocellular carcinoma with pelvic metastasis expressing AFP: a case report. *Front. Oncol.* 14: 1–5. doi:10.3389/fonc.2024.1489725
- Iqbal, S., Raiz, I., & Faiz, I., 2017. Surgical implications of portal vein variations and liver segmentations: A recent update. *J. Clin. Diagnostic Res.* 11: AE01–AE05. doi:10.7860/JCDR/2017/25028.9453
- Ji, J., Wang, H., Li, Y., Zheng, L., Yin, Y., Zou, Z., et al., 2016. Diagnostic

Evaluation of Des-Gamma-Carboxy Prothrombin versus α -Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. *PLoS One* 11: 1–17. doi:10.1371/journal.pone.0153227

- Johnston, D.E., 1999. Special considerations in interpreting liver function tests. *Am. Fam. Physician* 59.
- Joo, I., & Lee, J.M., 2016. Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoteric Acid-Enhanced MRI. *Liver Cancer* 5: 67–87. doi:10.1159/000367750
- Kaewdech, A., Sripongpun, P., Assawasuwannakit, S., Wetwittayakhleng, P., Jandee, S., Chamroonkul, N., et al., 2023. FAIL-T (AFP, AST, tumor size, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE. *Front. Med.* 10. doi:10.3389/fmed.2023.1077842
- Kim, D.H., Choi, S.H., Koo, B., Choi, S.J., Jang, H.J., Heo, S., et al., 2025. Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma. *Eur. Radiol.* 35: 4957–4966. doi:10.1007/s00330-025-11418-2
- Kim, D.Y., 2024. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. *J. Liver Cancer* 24: 62–70. doi:10.17998/jlc.2024.03.13
- Kim, H., Jang, M., & Park, Y.N., 2020. Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors. *J. Liver Cancer* 20: 17–24. doi:10.17998/jlc.20.1.17
- Kirkwood, B., & Sterne, J., 2003. Essential Medical Statistics. second edition. *Blackwell Publ. Co.*
- Kulkarni, N., Fung, A., Kambadakone, A.R., & Yeh, B.M., 2022. CT Techniques, Protocols, Advancements and Future Directions in Liver Diseases 1–29. doi:10.1016/j.mric.2021.05.002.CT
- Kusuma, I.F., Ratnasari, N., & Bayupurnama, P., 2019. RASIO ALPHA FETOPROTEIN-L3/ALPHA FETOPROTEIN (AFP-L3%) SEBAGAI FAKTOR PREDIKTOR MORTALITAS PASIEN DENGAN KARSINOMA HEPATOSELULER DI RSUP DR. SARDJITO. Gadjah Mada.
- Lee, W.C., 2021. Value of alpha-fetoprotein in hepatocellular carcinoma. *Transl. Gastroenterol. Hepatol.* 6: 2019–2022. doi:10.21037/tgh.2019.12.19
- Li, J., Li, Y., Zhong, J., Du, J., Chen, J., Shi, J., et al., 2025. Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas. *Front. Immunol.* 16: 1–14. doi:10.3389/fimmu.2025.1643290
- Li, Y., Xu, A., Jia, S., & Huang, J., 2019. Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma (review). *Oncol. Lett.*

17: 4222–4228. doi:10.3892/ol.2019.10127

- Liang, Y., Xu, F., Guo, Y., Lai, L., Jiang, X., Wei, X., et al., 2021. Diagnostic performance of LI-RADS for MRI and CT detection of HCC : A systematic review and diagnostic meta-analysis. *Eur. J. Radiol.* 134: 109404. doi:10.1016/j.ejrad.2020.109404
- Liao, T.Y., Liaw, C.C., Hsu, H.C., Hsieh, C.H., Chang, J.W.C., & Juan, Y.H., 2019. Extrahepatic portal venous obstruction with hepatic enzyme elevation resembling hepatitis in patients with cancer. *In Vivo (Brooklyn)*. 33: 1697–1702. doi:10.21873/invivo.11658
- Liou, W.L., Tan, T.J.Y., Chen, K., Goh, G.B.B., Chang, J.P.E., & Tan, C.K., 2023. Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades. *JGH Open* 7: 377–386. doi:10.1002/jgh3.12910
- Liu, C., Xiao, G.Q., Yan, L.N., Li, B., Jiang, L., Wen, T.F., et al., 2013. Value of α -fetoprotein in association with clinicopathological features of hepatocellular carcinoma. *World J. Gastroenterol.* 19: 1811–1819. doi:10.3748/wjg.v19.i11.1811
- Llovet, J.M., & Bruix, J., 2003. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 37. doi:10.1053/jhep.2003.50047
- Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., et al., 2021. Hepatocellular carcinoma. *Nat. Rev. Dis. Prim.* 7. doi:10.1038/s41572-020-00240-3
- Llovet, J.M., Real, M.I., Montaña, X., Planas, R., Coll, S., Aponte, J., et al., 2002. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. *Lancet* 359. doi:10.1016/S0140-6736(02)08649-X
- Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al., 2008. Sorafenib in Advanced Hepatocellular Carcinoma. *N. Engl. J. Med.* 359: 378–390. doi:10.1056/nejmoa0708857
- Luo, M.Y., Shan, H., Jiang, Z.B., Li, L.F., & Huang, H.Q., 2003. Study on hepatocellular carcinoma-associated hepatic arteriovenous shunt using multidetector CT. *World J. Gastroenterol.* 9: 2455–2459. doi:10.3748/wjg.v9.i11.2455
- Marrero, J.A., Kulik, L.M., Sirlin, C.B., Zhu, A.X., Finn, R.S., Abecassis, M.M., et al., 2018. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 68: 723–750. doi:10.1002/hep.29913
- Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., et al., 1996. LIVER TRANSPLANTATION FOR THE TREATMENT OF SMALL HEPATOCELLULAR CARCINOMAS IN PATIENTS WITH

- CIRRHOSIS. *N. Engl. J. Med.* 334: 693–699.
doi:10.1056/NEJM199603143341104
- McGlynn, K.A., Sahasrabudde, V. V., Campbell, P.T., Graubard, B.I., Chen, J., Schwartz, L.M., et al., 2015. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: Results from the Liver Cancer Pooling Project. *Br. J. Cancer* 112: 1266–1272.
doi:10.1038/bjc.2015.58
- Murugavel, K.G., Mathews, S., Jayanthi, V., Shankar, E.M., Hari, R., Surendran, R., et al., 2008. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies. *Int. J. Infect. Dis.* 12. doi:10.1016/j.ijid.2008.04.010
- Nakashima, Y., Nakashima, O., Tanaka, M., Okuda, K., Nakashima, M., & Kojiro, M., 2003. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. *Hepatol. Res.* 26: 142–147.
doi:10.1016/S1386-6346(03)00007-X
- Napitupulu, E.N., Pudjomartono, B., & Ekowati, A., 2018. KORELASI SERUM ALFA FETOPROTEIN DENGAN UKURAN DAN JUMLAH TUMOR PADA KARSINOMA HEPATOSELULER. Gadjah Mada.
- Nathani, P., Gopal, P., Rich, N., Yopp, A., Yokoo, T., John, B., et al., 2021. Hepatocellular carcinoma tumour volume doubling time: A systematic review and meta-analysis. *Gut* 70: 401–407. doi:10.1136/gutjnl-2020-321040
- Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K.H., Elsharkawy, A.M., et al., 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science (80-.)*. 317: 121–124.
doi:10.1126/science.1140485
- Ngan, H., & Peh, W.C.G., 1997. Arteriovenous shunting in hepatocellular carcinoma: Its prevalence and clinical significance. *Brain Lang.* 52: 36–40.
doi:10.1016/s0009-9260(97)80303-0
- Oh, D., Shin, S.W., Park, H.C., Cho, S.K., Lim, D.H., & Paik, S.W., 2015. Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy. *Cancer Res. Treat.* 47: 251–258. doi:10.4143/crt.2014.011
- Park, J.W., Chen, M., Colombo, M., Roberts, L.R., Schwartz, M., Chen, P.J., et al., 2015. Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. *Liver Int.* 35: 2155–2166.
doi:10.1111/liv.12818
- Paulsen, F., Böckers, T.M., & Waschke, J., 2019. Sobotta Anatomy Textbook, Elsevier.
- Putz & Pabst, R., 2006. Sobotta Atlas of Human Anatomy, Volume 2. *Sobotta Atlas Hum. Anat.* 2: 1–406.
- Ramadhini, A.S., Ratnasari, N., Sofia, N.A., & Indrarti, F., 2022. Korelasi Serum

Alfa-Fetoprotein (AFP) dengan Tingkat Keparahan Karsinoma Hepatoseluler Berdasarkan Sistem Staging Barcelona Clinic Liver Cancer (BCLC) di RSUP Dr. Sardjito Yogyakarta. Gadjah Mada.

- Reig, M., Forner, A., Rimola, J., Ferrer-fàbrega, J., Burrel, M., Garcia-criado, Á., et al., 2023. HHS Public Access Author manuscript recommendation : The 2022 update. *J. Hepatol.* 76: 681–693. doi:10.1016/j.jhep.2021.11.018.BCLC
- Reig, M., Forner, A., Rimola, J., Ferrer-fàbrega, J., Burrel, M., Garcia-criado, Á., et al., 2022. Review BCLC strategy for prognosis prediction and treatment recommendation : The 2022 update q. *J. Hepatol.* 76: 681–693. doi:10.1016/j.jhep.2021.11.018
- Richardson, P., Duan, Z., Kramer, J., Davila, J.A., Tyson, G.L., & El-Serag, H.B., 2012. Determinants of Serum Alpha-Fetoprotein Levels in Hepatitis C-Infected Patients. *Clin. Gastroenterol. Hepatol.* 10. doi:10.1016/j.cgh.2011.11.025
- Roberts, L.R., Sirlin, C.B., Zaiem, F., Almasri, J., Prokop, L.J., Heimbach, J.K., et al., 2018. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. *Hepatology* 67: 401–421. doi:10.1002/hep.29487
- Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C.J., Vignat, J., et al., 2022. Global burden of primary liver cancer in 2020 and predictions to 2040. *J. Hepatol.* 77. doi:10.1016/j.jhep.2022.08.021
- Rusie, D., Mercan Stanciu, A., Toma, L., & Iliescu, E.L., 2022. Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals. *Cureus* 14. doi:10.7759/cureus.24506
- Schima, W., & Heiken, J., 2018. LI-RADS v2017 for liver nodules: How we read and report. *Cancer Imaging* 18: 1–11. doi:10.1186/s40644-018-0149-5
- Schlageter, M., Terracciano, L.M., D'Angelo, S., & Sorrentino, P., 2014. Histopathology of hepatocellular carcinoma. *World J. Gastroenterol.* 20: 15955–15964. doi:10.3748/wjg.v20.i43.15955
- Septianti, R., Ratnasari, N., & Nurdjanah, S., 2018. Perbedaan rasio alpha fetoprotein-I3 / alpha fetoprotein (afp- 13%) pada karsinoma hepatoseluler berdasarkan sistim staging barcelona clinic liver cancer (bclc). Gadjah Mada.
- Sevim, S., Dicle, O., Gezer, N.S., Barış, M.M., Altay, C., & Akın, I.B., 2019. How high is the inter-observer reproducibility in the LIRADS reporting system? *Polish J. Radiol.* 84: e464–e469. doi:10.5114/PJR.2019.90090
- Shi, J., Wang, X., Zhou, J., Fan, J., & Gao, Q., 2016. Case Report of Small Hepatocellular Carcinoma Complicated with an Isolated Portal Vein Tumor. *Clin Oncol* 1: 1–3.
- Si, Y.Q., Wang, X.Q., Fan, G., Wang, C.Y., Zheng, Y.W., Song, X., et al., 2020. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation.

Infect. Agent. Cancer 15: 1–7. doi:10.1186/s13027-020-00337-0

- Siddiqui, M.T.U.H., Fareed, G., Khan, M.R., Riaz, A., & Hamid, S.S., 2023. Portal vein thrombosis in patients with hepatocellular carcinoma and early cirrhosis-prevalence and risk factors. *Ecancermedicalscience* 17. doi:10.3332/ecancer.2023.1581
- Singal, A.G., Llovet, J.M., Yarchoan, M., Mehta, N., Heimbach, J.K., Dawson, L.A., et al., 2023. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology* 78. doi:10.1097/HEP.0000000000000466
- Sinn, D.H., Gwak, G.Y., Cho, J., Paik, S.W., & Yoo, B.C., 2014. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: Analysis of a nationwide cohort. *PLoS One* 9. doi:10.1371/journal.pone.0112184
- Sun, T., Ren, Y., Kan, X., Chen, L., Zhang, W., Yang, F., et al., 2020. Advanced Hepatocellular Carcinoma With Hepatic Arteriportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib. *Front. Mol. Biosci.* 7: 1–8. doi:10.3389/fmolb.2020.607520
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* 71: 209–249. doi:10.3322/caac.21660
- Talian, L.I.I., & Clip, P.R., 2000. Prospective Validation of the CLIP Score : A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma 840–845. doi:10.1053/he.2000.5628
- Tandon, P., & Garcia-Tsao, G., 2009. Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. *Liver Int.* 29: 502–510. doi:10.1111/j.1478-3231.2008.01957.x
- Tarao, K., Nozaki, A., Ikeda, T., Sato, A., Komatsu, H., Komatsu, T., et al., 2019. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta-analytic assessment. *Cancer Med.* 8: 1054–1065. doi:10.1002/cam4.1998
- Trevisani, F., D’Intino, P.E., Morselli-Labate, A.M., Mazzella, G., Accogli, E., Caraceni, P., et al., 2001. Serum α -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. *J. Hepatol.* 34: 570–575. doi:10.1016/S0168-8278(00)00053-2
- Tsoris, A., & Marljar, C.A., 2019. Use Of The Child Pugh Score In Liver Disease, StatPearls.
- Turshudzhyan, A., & Wu, G.Y., 2022. Persistently Rising Alpha-fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Review. *J. Clin. Transl. Hepatol.* 10: 159–163. doi:10.14218/JCTH.2021.00176
- Vernon, H., & Kasi, A., 2019. Anatomy, Abdomen and Pelvis, Liver, StatPearls.

- Wang, F., Gao, S., Wu, M., Zhao, D., Sun, H., Yav, S., et al., 2023. The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE. *BMC Gastroenterol.* 23: 1–8. doi:10.1186/s12876-023-02719-1
- Wölfel, G., Ostheim, E., Staub, A., Tümen, D., Heumann, P., Schmid, S., et al., 2023. The p53 Family of Transcription Factors Represses the Alpha-fetoprotein Gene Expression in Hepatocellular Carcinoma. *J. Gastrointest. Liver Dis.* 32: 346–355. doi:10.15403/JGLD-4055
- Wu, H., Zhao, W., Zhang, J., Han, J., & Liu, S., 2018. Clinical characteristics of hepatic Arterioportal shunts associated with hepatocellular carcinoma. *BMC Gastroenterol.* 18: 1–6. doi:10.1186/s12876-018-0899-3
- Wu, M., Yu, H., Pang, S., Liu, A., & Liu, J., 2025. Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma. *BMC Med. Imaging* 25. doi:10.1186/s12880-025-01588-2
- Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A., & Roberts, L.R., 2019. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nat. Rev. Gastroenterol. Hepatol.* doi:10.1038/s41575-019-0186-y
- Yao, M., Zhao, J., & Lu, F., 2016. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. *Oncotarget* 7: 3702–3708. doi:10.18632/oncotarget.6913
- Zeng, S., Wang, Z., Zhu, Q., Li, X., Ren, H., Qian, B., et al., 2023. Identification of risk and prognostic factors for intrahepatic vascular invasion in patients with hepatocellular carcinoma: a population-based study. *Transl. Cancer Res.* 12. doi:10.21037/tcr-22-1912
- Zhang, Jiabin, Chen, G., Zhang, P., Zhang, Jiaying, Li, X., Gan, D., et al., 2020. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. *PLoS One* 15: 1–21. doi:10.1371/journal.pone.0228857
- Zhou, Z., Cao, S., Chen, C., Chen, J., Xu, X., Liu, Y., et al., 2023. A Novel Nomogram for the Preoperative Prediction of Edmondson-Steiner Grade III-IV in Hepatocellular Carcinoma Patients. *J. Hepatocell. Carcinoma* 10: 1399–1409. doi:10.2147/JHC.S417878